Artiva Biotherapeutics (ARTV) Competitors

$8.72 -0.50 (-5.47%)

As of 01:59 PM Eastern

ARTV vs. CVAC, CRON, SVRA, PHAT, and CGEM

Should you buy Artiva Biotherapeutics stock or one of its competitors? MarketBeat compares Artiva Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Artiva Biotherapeutics include CureVac (CVAC), Cronos Group (CRON), Savara (SVRA), Phathom Pharmaceuticals (PHAT), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.

How does Artiva Biotherapeutics compare to CureVac?

Artiva Biotherapeutics (NASDAQ:ARTV) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

17.3% of CureVac shares are held by institutional investors. 21.4% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CureVac has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	861.84	-$83.86M	-$3.54	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Artiva Biotherapeutics presently has a consensus price target of $39.00, suggesting a potential upside of 347.45%. CureVac has a consensus price target of $6.83, suggesting a potential upside of 46.64%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Artiva Biotherapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Artiva Biotherapeutics had 8 more articles in the media than CureVac. MarketBeat recorded 8 mentions for Artiva Biotherapeutics and 0 mentions for CureVac. Artiva Biotherapeutics' average media sentiment score of 0.55 beat CureVac's score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Artiva Biotherapeutics	Positive
CureVac	Neutral

CureVac has a net margin of 199.92% compared to Artiva Biotherapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
CureVac	199.92%	-23.03%	-19.09%

Artiva Biotherapeutics has a beta of 2.86, meaning that its share price is 186% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Summary

Artiva Biotherapeutics beats CureVac on 9 of the 17 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Cronos Group?

Artiva Biotherapeutics (NASDAQ:ARTV) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Artiva Biotherapeutics has a beta of 2.86, indicating that its share price is 186% more volatile than the broader market. Comparatively, Cronos Group has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Artiva Biotherapeutics currently has a consensus price target of $39.00, indicating a potential upside of 347.45%. Cronos Group has a consensus price target of $2.30, indicating a potential downside of 12.38%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Cronos Group has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	861.84	-$83.86M	-$3.54	N/A
Cronos Group	$146.59M	6.74	-$9.45M	$0.01	262.50

In the previous week, Cronos Group had 2 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 10 mentions for Cronos Group and 8 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.55 beat Cronos Group's score of 0.40 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cronos Group	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Artiva Biotherapeutics has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. Cronos Group's return on equity of -1.26% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Cronos Group	-1.14%	-1.26%	-1.20%

8.7% of Cronos Group shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 7.8% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Artiva Biotherapeutics beats Cronos Group on 9 of the 17 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Savara?

Artiva Biotherapeutics (NASDAQ:ARTV) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Artiva Biotherapeutics has a beta of 2.86, meaning that its stock price is 186% more volatile than the broader market. Comparatively, Savara has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

In the previous week, Savara had 10 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 18 mentions for Savara and 8 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.55 beat Savara's score of -0.79 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

87.9% of Savara shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Artiva Biotherapeutics' return on equity of -73.15% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Savara	N/A	-87.19%	-66.42%

Artiva Biotherapeutics currently has a consensus target price of $39.00, indicating a potential upside of 347.45%. Savara has a consensus target price of $9.13, indicating a potential upside of 90.70%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Artiva Biotherapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	861.84	-$83.86M	-$3.54	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Summary

Artiva Biotherapeutics beats Savara on 10 of the 14 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Phathom Pharmaceuticals?

Artiva Biotherapeutics (NASDAQ:ARTV) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Artiva Biotherapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 21.4% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Artiva Biotherapeutics has a beta of 2.86, indicating that its share price is 186% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

Artiva Biotherapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	861.84	-$83.86M	-$3.54	N/A
Phathom Pharmaceuticals	$175.11M	5.36	-$221.25M	-$2.12	N/A

In the previous week, Artiva Biotherapeutics had 6 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 8 mentions for Artiva Biotherapeutics and 2 mentions for Phathom Pharmaceuticals. Artiva Biotherapeutics' average media sentiment score of 0.55 beat Phathom Pharmaceuticals' score of 0.47 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phathom Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Artiva Biotherapeutics currently has a consensus target price of $39.00, indicating a potential upside of 347.45%. Phathom Pharmaceuticals has a consensus target price of $25.00, indicating a potential upside of 112.28%. Given Artiva Biotherapeutics' higher probable upside, equities research analysts plainly believe Artiva Biotherapeutics is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Artiva Biotherapeutics beats Phathom Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Cullinan Therapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Artiva Biotherapeutics presently has a consensus target price of $39.00, suggesting a potential upside of 347.45%. Cullinan Therapeutics has a consensus target price of $30.75, suggesting a potential upside of 122.20%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cullinan Therapeutics' return on equity of -51.45% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Artiva Biotherapeutics has a beta of 2.86, indicating that its share price is 186% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market.

86.3% of Cullinan Therapeutics shares are held by institutional investors. 21.4% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Artiva Biotherapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	861.84	-$83.86M	-$3.54	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 9 mentions for Cullinan Therapeutics and 8 mentions for Artiva Biotherapeutics. Cullinan Therapeutics' average media sentiment score of 0.71 beat Artiva Biotherapeutics' score of 0.55 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Artiva Biotherapeutics beats Cullinan Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Artiva Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTV vs. The Competition

Export

Metric	Artiva Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$215.81M	$3.27B	$6.28B	$12.14B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-2.47	18.56	20.61	25.12
Price / Sales	861.84	282.45	581.13	92.21
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	1.95	6.60	9.74	6.62
Net Income	-$83.86M	$24.30M	$3.55B	$335.39M
7 Day Performance	-18.01%	-3.08%	-1.79%	-1.72%
1 Month Performance	-30.55%	-7.43%	-3.65%	-1.61%
1 Year Performance	331.49%	52.73%	29.85%	27.79%

Artiva Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARTV Artiva Biotherapeutics	4.0466 of 5 stars	$8.72 -5.5%	$39.00 +347.5%	+354.2%	$215.81M	$250K	N/A	81	Analyst Downgrade
CVAC CureVac	N/A	$4.66 flat	$6.83 +46.6%	N/A	$1.05B	$70.74M	6.47	880
CRON Cronos Group	1.5451 of 5 stars	$2.77 +0.7%	$2.30 -17.0%	+22.4%	$1.04B	$146.59M	N/A	450	Analyst Upgrade
SVRA Savara	2.3137 of 5 stars	$5.08 -0.8%	$9.13 +79.6%	+59.9%	$1.04B	N/A	N/A	20	Positive News Earnings Report Analyst Revision
PHAT Phathom Pharmaceuticals	2.6504 of 5 stars	$12.53 +2.5%	$25.00 +99.5%	+178.5%	$999.39M	$175.11M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTV) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artiva Biotherapeutics (ARTV) Competitors

ARTV vs. CVAC, CRON, SVRA, PHAT, and CGEM

How does Artiva Biotherapeutics compare to CureVac?

Summary

How does Artiva Biotherapeutics compare to Cronos Group?

Summary

How does Artiva Biotherapeutics compare to Savara?

Summary

How does Artiva Biotherapeutics compare to Phathom Pharmaceuticals?

Summary

How does Artiva Biotherapeutics compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV vs. The Competition

Artiva Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artiva Biotherapeutics (ARTV) Competitors

ARTV vs. CVAC, CRON, SVRA, PHAT, and CGEM

How does Artiva Biotherapeutics compare to CureVac?

Do insiders & institutionals have more ownership in ARTV or CVAC?

Which has stronger earnings and valuation, ARTV or CVAC?

Do analysts recommend ARTV or CVAC?

Does the media refer more to ARTV or CVAC?

Is ARTV or CVAC more profitable?

Which has more volatility and risk, ARTV or CVAC?

Summary

How does Artiva Biotherapeutics compare to Cronos Group?

Which has more risk and volatility, ARTV or CRON?

Do analysts rate ARTV or CRON?

Which has preferable earnings and valuation, ARTV or CRON?

Does the media refer more to ARTV or CRON?

Is ARTV or CRON more profitable?

Do institutionals and insiders believe in ARTV or CRON?

Summary

How does Artiva Biotherapeutics compare to Savara?

Which has more risk and volatility, ARTV or SVRA?

Does the media favor ARTV or SVRA?

Do institutionals and insiders believe in ARTV or SVRA?

Is ARTV or SVRA more profitable?

Do analysts recommend ARTV or SVRA?

Which has stronger earnings and valuation, ARTV or SVRA?

Summary

How does Artiva Biotherapeutics compare to Phathom Pharmaceuticals?

Is ARTV or PHAT more profitable?

Do insiders & institutionals believe in ARTV or PHAT?

Which has more risk and volatility, ARTV or PHAT?

Which has stronger earnings & valuation, ARTV or PHAT?

Does the media favor ARTV or PHAT?

Do analysts rate ARTV or PHAT?

Summary

How does Artiva Biotherapeutics compare to Cullinan Therapeutics?

Do analysts prefer ARTV or CGEM?

Is ARTV or CGEM more profitable?

Which has more risk & volatility, ARTV or CGEM?

Do institutionals and insiders have more ownership in ARTV or CGEM?

Which has preferable valuation & earnings, ARTV or CGEM?

Does the media prefer ARTV or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV vs. The Competition

Artiva Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools